Palatin Technologies (PTN) Completes Sale of Vyleesi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million
December 20, 2023 7:30 AM ESTPalatin to receive $12 million upfront, plus sales-based milestones of up to $159 millionPalatin's focus is solely on its development and clinical pipeline based on the melanocortin receptor system
CRANBURY, N.J., Dec. 20, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the sale of... More
